Industry veteran with deep expertise in biopharmaceutical services and supply will lead the next phase of growth and global expansion Company’s drug delivery technologies are used by leading biopharmaceutical developers to improve the efficiency, targeting, and safety profile of novel therapeutics Valencia, Spain and Boston, MA, November 16, 2021 – Polypeptide Therapeutic Solutions (PTS), a…
Arcline Investment Management (“Arcline”), a growth-oriented private equity firm with $4.3 billion of cumulative capital commitments, today announced the acquisition of Polypeptide Therapeutic Solutions, S.L. (“PTS” or “the Company”) from Columbus Venture Partners. PTS is a leading GMP-grade manufacturer of polyamino-acid (PAA) based nanoparticle encapsulation technology for advanced drug delivery applications, including mRNA, DNA, cell therapies,…
Polypeptide Therapeutic Solutions, S.L. ha desarrollado con éxito durante 2018 un proyecto denominado “DESARROLLO Y VALIDACIÓN DE METODOLOGÍAS ANALÍTICAS PARA ANÁLISIS DE HIDROGELES COMO MATRIZ DE MATERIALES POLIPEPTÍDICOS” para el que ha contado con el apoyo de la Agencia Valenciana de la Innovación, a través de su programa de apoyo “Promoción del talento”, en su…
A novel strategy developed by Aroa Duro-Castaño, Vicent J. Nebot, María J. Vicent and co-workers to produce nanosized drug carriers may improve the anticancer drug activity of polymer therapeutics and patient treatment http://onlinelibrary.wiley.com/doi/10.1002/adma.201770280/abstract